Fool - Investing News·Jun 27, 2026
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could MeanThis biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing clinical-stage developments.
Oruka Therapeutics, Inc.(ORKA)Earnings, Financials & Key Ratios
ORKA•NASDAQ
$84.50
Price updated Jul 7, 2026
AboutOruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Show more
- Revenue$0
- EBITDA-$122M-38.4%
- Net Income-$105M-25.9%
- EPS (Diluted)-2.31+53.7%
- ROE-24.69%+37.5%
ORKA Price & Volume
Oruka Therapeutics, Inc. (ORKA) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Cash Runway Sustainability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical development funding gap
Key Thesis Takeaways
- Oruka Therapeutics faces a precarious financial outlook as it advances its proprietary antibody platform, characterized by a lack of commercial revenue and widening quarterly operating losses that reached $36.4 million in 2026Q1.
- The company's reliance on external financing to fund intensive R&D, which totaled $29.1 million in the most recent quarter, creates significant exposure to dilutive capital raises.
- Investors should monitor the company's ability to achieve clinical milestones, as the current cash position of $49.5 million appears insufficient to sustain long-term operations without further liquidity events.
Verdict Logic
the company's rapid depletion of liquidity, evidenced by a cash balance of only $49.5 million against quarterly operating losses of $36.4 million, suggests a high probability of near-term dilutive financing.
ORKA Growth Metrics
Oruka Therapeutics, Inc. (ORKA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-10.45%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM54.48%
Return on Capital
10 Years-56.44%
5 Years-33.24%
3 Years-30.35%
Last Year-28.51%
ORKA Recent Earnings
Oruka Therapeutics, Inc. (ORKA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (75%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.48+12.2%
$0.55
Rev
—
—
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.45+26.2%
$0.61
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.55+1.8%
$0.56
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.46+4.2%
$0.48
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.48vs $0.55+12.2% | — |
| Q2 2026 | Mar 12, 2026 | $0.45vs $0.61+26.2% | — |
| Q4 2025 | Nov 12, 2025 | $0.55vs $0.56+1.8% | — |
| Q3 2025 | Aug 11, 2025 | $0.46vs $0.48+4.2% | — |
Based on last 12 quarters of dataView full earnings history →
Latest ORKA News
Recent stock market news and headlines for Oruka Therapeutics, Inc. (ORKA)
The Motley Fool·Jun 24, 2026
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?Arjun Agarwal sold 10,290 shares for a transaction value of approximately ~$608,000, based on a weighted average price of $59.07 per share on May 18, 2026. This sale represented 38.5% of Agarwal's direct holdings, reducing direct ownership from 26,696 to 16,406 shares.
Peers Comparison
Key metrics vs top competitors for Oruka Therapeutics, Inc. (ORKA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $84.50 | $3.16B | -36.58 | — | — | -24.69% | — | |
| $676.23 | $70.26B | 16.30 | 0.99% | 29.65% | 14.32% | — | |
| $4.12 | $1.15B | -4.29 | — | — | -161.87% | — | |
| $27.67 | $3.46B | -212.85 | 91.34% | -0.57% | -1.41% | — | |
| $21.53 | $2.22B | -20.70 | 20.6% | -67.85% | -23.43% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — |
Compare ORKA vs Peers
Oruka Therapeutics, Inc. (ORKA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ORKA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ORKA Frequently Asked Questions
Oruka Therapeutics, Inc. (ORKA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is ORKA profitable?
Oruka Therapeutics, Inc. (ORKA) reported a net loss of $116.3M for fiscal year 2025.
Dividend & Returns
What is ORKA's return on equity?
Oruka Therapeutics, Inc. (ORKA) has a return on equity (ROE) of -24.7%. Negative ROE indicates the company is unprofitable.
What is Oruka Therapeutics, Inc.'s free cash flow?
Oruka Therapeutics, Inc. (ORKA) had negative free cash flow of $91.2M in fiscal year 2025, likely due to heavy capital investments.